Explore the words cloud of the DosiKit project. It provides you a very rough idea of what is the project "DosiKit" about.
The following table provides information about the project.
|Coordinator Country||France [FR]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-08-01 to 2020-01-31|
Take a look of project's partnership.
Acubens was founded in 2014, to develop and commercialize new game-changer medical diagnostic devices around NRBC emergency. Our team gathers young and experimented doctors, and seasoned business managers, uniting their competencies to develop nuclear/radiological/biological innovative transportable biodosimetry devices. Nuclear/radiological accident can expose individuals to radiation, with the need for fast triage of potentially exposed people requiring immediate medical care. There is today a lack of irradiation biodosimetry tools that can be used in the field, by non-specialist staff, giving immediate results and exposure cartography in case of Partial-Body irradiation (PBI). To fulfil this critical unmet need for better initial crisis management, we invented the DosiKit device and fast test (45 minutes) to identify and classify irradiated individuals, directly in the field. This development was initiated in 2009 by the French Atomic Energy Commission within the European Commission program, BOOSTER (‘BiO-dOSimetric Tools for triagE to Responders’), and then continued by Acubens. DosiKit technology is protected by 3 international patents and has reached TRL6 with a prototype validated in a large-scale exercise performed with the French army. Several collaborations are undergoing for biological validation with French research institute and hospitals. Scientific and technical development was published in 3 scientific publications and many international oral communications. A strong contact has established with French, Germany, Israel, US and Singapore armies (LoI). This DosiKit product will be on the market in 2022, starting in Europe and then extending worldwide. Forecasted sales revenue is 15 M€ in 2024. The objectives of this phase 1 SME-Instrument are: (1) the final Biological and Technological validation of the device, (2) IP, FTO, Regulatory and risk assessment studies and (3) a market survey in Europe and USA to schedule our commercial actions.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DOSIKIT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DOSIKIT" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
IOT and cloud computing for online medical analysis service platformRead More
Utilizing an innovative chemical platform to defeat antimicrobial resistanceRead More